Short answer
Aurinia Pharmaceuticals Inc. (AUPH) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for the three months ended June 30, 2026.
Aurinia Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for the three months ended June 30, 2026
- Press release issued August 6, 2026, with financial details in Exhibit 99.1
- Market focus: quarterly performance, outlook, and any updated operating metrics in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $83.2M, up 19%; LUPKYNIS sales $79.4M, confirming continued commercial momentum
- Six-month net income $71.8M, up 60%; diluted EPS $0.53 versus $0.32
- Operating cash flow $85.1M, up 87%, supporting internally funded operations and development
- Cash, restricted cash and investments $443.1M at June 30, 2026, despite $74.9M spent repurchasing 5.0M shares
- 2026 guidance reiterated: revenue $315M–$325M and LUPKYNIS sales $305M–$315M; PRESERVE Phase 4 study adds combination-treatment upside
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aurinia Pharmaceuticals Inc. 8-K filings
Get the next AUPH 8-K as it lands
Follow AUPH for push alerts, or ask the research agent what this filing means.